Authors:
Kim, D
Wang, LP
Caldwell, CG
Chen, P
Finke, PE
Oates, B
MacCoss, M
Mills, SG
Malkowitz, L
Gould, SL
DeMartino, JA
Springer, MS
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Carver, G
Carella, A
Holmes, K
Lineberger, J
Schleif, WA
Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Authors:
Kim, D
Wang, LP
Caldwell, CG
Chen, P
Finke, PE
Oates, B
MacCoss, M
Mills, SG
Malkowitz, L
Gould, SL
DeMartino, JA
Springer, MS
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Carver, G
Carella, A
Holmes, K
Lineberger, J
Schleif, WA
Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
Authors:
Willoughby, CA
Berk, SC
Rosauer, KG
Degrado, S
Chapman, KT
Gould, SL
Springer, MS
Malkowitz, L
Schleif, WA
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Holmes, K
Lineberger, J
Carella, A
Carver, G
Emini, EA
Citation: Ca. Willoughby et al., Combinatorial synthesis of CCR5 antagonists, BIOORG MED, 11(24), 2001, pp. 3137-3141
Authors:
Hale, JJ
Budhu, RJ
Holson, EB
Finke, PE
Oates, B
Mills, SG
MacCoss, M
Gould, SL
DeMartino, JA
Springer, MS
Siciliano, S
Malkowitz, L
Schleif, WA
Hazuda, D
Miller, M
Kessler, J
Danzeisen, R
Holmes, K
Lineberger, J
Carella, A
Carver, G
Emini, E
Citation: Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Authors:
Dorn, CP
Finke, PE
Oates, B
Budhu, RJ
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Authors:
Finke, PE
Meurer, LC
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Authors:
Finke, PE
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Gould, SL
DeMartino, JA
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
Authors:
Spichiger, D
Carver, G
Dobe, C
Bendix, J
Tregenna-Piggott, PLW
Meier, R
Zahn, G
Citation: D. Spichiger et al., Electronic Raman transitions from the vanadium(III) hexa-aqua cation, in guanidinium vanadium sulphate, CHEM P LETT, 337(4-6), 2001, pp. 391-397